Georgia Ragia

List of Publications by Year
in descending order

36 papers	825 citations	566801 15 h-index	500791 28 g-index
37 all docs	37 docs citations	37 times ranked	1277 citing authors

#	ARTICLE	IF	CITATIONS
1	Genetic polymorphisms of drug‐metabolizing enzymes CYP2D6, CYP2C9, CYP2C19 and CYP3A5 in the Greek population. Fundamental and Clinical Pharmacology, 2007, 21, 419-426.	1.0	106
2	Presence of *CYP2C9*3* allele increases risk for hypoglycemia in Type 2 diabetic patients treated with sulfonylureas. Pharmacogenomics, 2009, 10, 1781-1787.	0.6	84
3	Inhibition of SARS-CoV-2 entry through the ACE2/TMPRSS2 pathway: a promising approach for uncovering early COVID-19 drug therapies. European Journal of Clinical Pharmacology, 2020, 76, 1623-1630.	0.8	81
4	Pharmacogenomics of oral antidiabetic medications: current data and pharmacoepigenomic perspective. Pharmacogenomics, 2011, 12, 1161-1191.	0.6	65
5	Need for reassessment of reported *CYP2C19* allele frequencies in various populations in view of *CYP2C19*17* discovery: the case of Greece. Pharmacogenomics, 2009, 10, 43-49.	0.6	62
6	Pharmacogenetics of coumarinic oral anticoagulants. Pharmacogenomics, 2010, 11, 493-496.	0.6	61
7	Association of KCNJ11 E23K gene polymorphism with hypoglycemia in sulfonylurea-treated Type 2 diabetic patients. Diabetes Research and Clinical Practice, 2012, 98, 119-124.	1.1	32
8	Endothelial nitric oxide synthase gene polymorphisms -786T >C and 894G >T in coronary artery bypass graft surgery patients. Human Genomics, 2010, 4, 375.	1.4	28
9	Assessing COVID-19 susceptibility through analysis of the genetic and epigenetic diversity of ACE2-mediated SARS-CoV-2 entry. Pharmacogenomics, 2020, 21, 1311-1329.	0.6	28
10	Genotyping ofCYP2C9andVKORC1in the Arabic Population of Al-Ahsa, Saudi Arabia. BioMed Research International, 2013, 2013, 1-6.	0.9	25
11	Epigenetics-by-Sex Interaction for Coronary Artery Disease Risk Conferred by the Cystathionine Î³-Lyase Gene Promoter Methylation. OMICS A Journal of Integrative Biology, 2017, 21, 741-748.	1.0	19
12	Association of VKORC1 â̂'1639 G>A polymorphism with carotid intimaâ€"media thickness in type 2 diabetes mellitus. Diabetes Research and Clinical Practice, 2011, 94, 236-241.	1.1	18
13	*POR*28* SNP is associated with lipid response to atorvastatin in children and adolescents with familial hypercholesterolemia. Pharmacogenomics, 2014, 15, 1963-1972.	0.6	17
14	Genetics of Obstructive Sleep Apnea: Vitamin D Receptor Gene Variation Affects Both Vitamin D Serum Concentration and Disease Susceptibility. OMICS A Journal of Integrative Biology, 2019, 23, 45-53.	1.0	17
15	Renin-angiotensin-aldosterone system gene polymorphisms in coronary artery bypass graft surgery patients. JRAAS - Journal of the Renin-Angiotensin-Aldosterone System, 2010, 11, 136-145.	1.0	16
16	Pharmacokinetic interactions of selective serotonin reuptake inhibitors with other commonly prescribed drugs in the era of pharmacogenomics. Drug Metabolism and Drug Interactions, 2012, 27, 19-31.	0.3	16
17	Personalized Medicine of Alcohol Addiction: Pharmacogenomics and Beyond. Current Pharmaceutical Biotechnology, 2017, 18, 221-230.	0.9	13
18	Metabolic Syndrome and Vitamin D Levels in Patients with Obstructive Sleep Apnea Syndrome. Metabolic Syndrome and Related Disorders, 2018, 16, 190-196.	0.5	13

#	Article	IF	Citations
19	Frequency of CYP450 enzyme gene polymorphisms in the Greek population: review of the literature, original findings and clinical significance. Drug Metabolism and Drug Interactions, 2014, 29, 235-248.	0.3	12
20	Association of Functional *VKORC1* Promoter Polymorphism with Occurrence and Clinical Aspects of Ischemic Stroke in a Greek Population. Disease Markers, 2013, 35, 641-646.	0.6	11
21	Lack of Association of the P450 Oxidoreductase *28 Single Nucleotide Polymorphism with the Lipid-Lowering Effect of Statins in Hypercholesterolemic Patients. Molecular Diagnosis and Therapy, 2014, 18, 323-31.	1.6	11
22	A novel acenocoumarol pharmacogenomic dosing algorithm for the Greek population of EU-PACT trial. Pharmacogenomics, 2017, 18, 23-34.	0.6	10
23	Association of monocyte chemoattractant protein-1 â⁻2518A>G polymorphism with occurrence, severity, and outcome in ischemic stroke. Neurological Sciences, 2013, 34, 1315-1320.	0.9	8
24	Search for Pharmacoepigenetic Correlations in Type 2 Diabetes Under Sulfonylurea Treatment. Experimental and Clinical Endocrinology and Diabetes, 2019, 127, 226-233.	0.6	8
25	Gender-dependent association of *TYMS*-TSER polymorphism with 5-fluorouracil or capecitabine-based chemotherapy toxicity. Pharmacogenomics, 2021, 22, 669-680.	0.6	8
26	Impact of CYP3A5 Gene Polymorphism on Efficacy of Simvastatin. Open Cardiovascular Medicine Journal, 2014, 8, 12-17.	0.6	8
27	Pharmacogenomics of anticoagulation therapy: the last 10 years. Pharmacogenomics, 2019, 20, 1113-1117.	0.6	7
28	CYP3A5 genotyping for assessing the efficacy of treatment with simvastatin and atorvastatin. Genetics and Molecular Biology, 2015, 38, 129-137.	0.6	6
29	*MTHFR* c.665C>T guided fluoropyrimidine therapy in cancer: gender-dependent effect on dose requirements. Drug Metabolism and Personalized Therapy, 2022, 37, 323-327.	0.3	6
30	Association study of the CTH 1364 G>T polymorphism with coronary artery disease in the Greek population. Drug Metabolism and Personalized Therapy, 2019, 34, .	0.3	5
31	Gene-gene interaction of Î¼-opioid receptor and GluR5 kainate receptor subunit is associated with smoking behavior in a Greek population: presence of a dose allele effect. Drug Metabolism and Personalized Therapy, 2015, 30, 129-135.	0.3	3
32	Pharmacogenomics of Oral Antidiabetic Drugs. , 2014, , 683-713.		2
33	Role of CYP4F2, CYP2C19, and CYP1A2 polymorphisms on acenocoumarol pharmacogenomic algorithm accuracy improvement in the Greek population: need for sub-phenotype analysis. Drug Metabolism and Personalized Therapy, 2017, 32, 183-190.	0.3	2
34	Research Highlights. Pharmacogenomics, 2012, 13, 261-264.	0.6	1
35	From Homer and Hippocrates to modern personalized medicine: is there a role for pharmacoepigenomics in the treatment of alcohol addiction?. Pharmacogenomics, 2018, 19, 513-516.	0.6	1
36	TCF7L2 rs7903146 C>T gene polymorphism is not associated with hypoglycemia in sulfonylurea-treated type 2 diabetic patients. Drug Metabolism and Personalized Therapy, 2021, .	0.3	1